Resverlogix
Company Information
Resverlogix is a Calgary biotechnology company developing small-molecule therapies that target epigenetic mechanisms involved in cardiovascular, metabolic, and inflammatory disease. Public company materials have long centered on bromodomain and extra-terminal protein inhibition and on its lead clinical program, apabetalone. The company’s positioning is that of a clinical-stage developer pursuing novel mechanisms in serious chronic diseases.
Industry Focus and Technologies
Small-molecule pharmaceuticals, epigenetics, bromodomain inhibition, cardiometabolic disease, inflammation, and clinical-stage biotechnology development.
Location
Calgary, Alberta, Canada
Company Size and Stage
Products, Platforms or Focus Areas
Apabetalone and related BET inhibitor programs, epigenetic small-molecule therapeutics, and development programs targeting cardiovascular, metabolic, renal, and inflammatory disease indications.